Kymab milestone payment

Schroders Capital Global Innovation

05 February 2024

 

Schroders Capital Global Innovation Trust Plc

Kymab milestone payment

Schroders Capital Global Innovation Trust plc (the "Company") is pleased to announce that it has received a $5.8 million (c. £4.6 million) distribution related to the first milestone of the Kymab sale to Sanofi.

In April 2021, the Company announced the completion of the sale of its shares in Kymab to Sanofi, generating initial proceeds of $87 million (£65 million). At that time, the Company explained there was the potential for additional contingent payments of up to $27 million (£20 million) subject to the achievement of various development and regulatory milestones. This announced payment reflects the first milestone event, with the potential for $21 million of further contingent payments in the future.

This uplift of c. £4.6 million will be reflected in the Company's unaudited NAV per share, dated Friday 2 February 2024, published later today.

Enquiries:

Schroder Investment Management Limited

Shilla Pindoria (Company Secretary)	0207 658 6000
Augustine Chipungu (Press)	0207 658 2106
John Spedding (Head of Investment Trusts)	0207 658 3206

 

END